{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:40:13Z","timestamp":1772250013342,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Elexacaftor\u2013tezacaftor\u2013ivacaftor (ETI) is a novel, highly effective CFTR modulator combination proven to enhance lung function and body weight in people with cystic fibrosis (pwCF) carrying a F508del mutation. Recently, we revealed significant reductions in abdominal symptoms (AS) in German, British, and Irish pwCF after 24\u201326\u00a0weeks of ETI using the CFAbd-Score, the first patient-reported outcome measure (PROM) specifically developed and validated for pwCF following FDA guidelines. Notably, many pwCF reported marked changes in their AS during the first days of the new treatment. To capture these immediate effects, we developed the CFAbd-day2day, a CF-specific GI-diary, following FDA and COSMIN guidelines.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    To prospectively capture the immediate dynamics of AS using the CFAbd-day2day 14\u00a0days before and 14\u201328\u00a0days after ETI initiation. In addition, we aim to provide validation steps of the novel PROM concerning sensitivity to changes.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    To develop the CFAbd-day2day, focus groups (community voice = pwCF and their proxies and CF specialists from different fields) were repeatedly consulted. Before and during the new ETI therapy, pwCF prospectively scored AS on a daily basis with the CFAbd-day2day.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Altogether, 45 pwCF attended in five CF centers prospectively completed the CFAbd-day2day before (mean \u00b1 sd:14 \u00b1 7\u00a0days) and after (mean \u00b1 sd: 28 \u00b1 23\u00a0days) ETI initiation. On the one hand, cumulative scores significantly decreased during the 3\u20134-week time frame after ETI initiation, compared to 2\u00a0weeks prior to therapy. On the other hand, many patients who revealed a relatively stable level of AS before ETI reported changes during the first days of treatment with the highly effective CFTR modulators. Factors like pain and flatulence increased in up to 21% of patients during the first 14\u00a0days of therapy, but they improved during days 15\u201327.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The CFAbd-day2day, specifically developed and in the process of validation to prospectively capture GI symptoms in pwCF, provides new substantial insights into the dynamics of AS in pwCF receiving a new treatment with ETI. This novel tool is also helpful in prospectively monitoring patients with specific GI problems. International implementation and further validation steps of the diary are ongoing.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1167407","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T01:13:13Z","timestamp":1698282793000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor\/tezacaftor\/ivacaftor using the novel CFAbd-day2day questionnaire"],"prefix":"10.3389","volume":"14","author":[{"given":"Jochen G.","family":"Mainz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Barucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilith","family":"Bechinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Duckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Polte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Sadrieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz","family":"N\u00e4hrlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"Eickmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Van Dullemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patience","family":"Eschenhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"L\u00fcth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Zagoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Graepler-Mainka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12890-019-0887-6","article-title":"Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study","volume":"19","author":"Bell","year":"2019","journal-title":"BMC Pulm. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/MPG.0000000000001868","article-title":"CFTR Protein Function Modulation Therapy Is Finally Targeting Cystic Fibrosis-related Gastrointestinal Disease","volume":"66","author":"Bodewes","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jcf.2020.04.001","article-title":"Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with Cystic Fibrosis","volume":"19","author":"Boon","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s10620-022-07812-1","article-title":"Cystic Fibrosis-Related Gut Dysbiosis: A Systematic Review","volume":"68","author":"Caley","year":"","journal-title":"Dig. Dis. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jcf.2023.01.010","article-title":"Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis","volume":"22","author":"Caley","year":"","journal-title":"J. Cyst. Fibros."},{"key":"B7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2\u20135 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B9","volume-title":"Deutsches mukoviszidose-register Berichtsband 2019","year":"2020"},{"key":"B10","first-page":"107","article-title":"A comparison of two pancreatin microsphere preparations in cystic fibrosis","volume":"105","author":"Elliott","year":"1992","journal-title":"N. Z. Med. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcf.2017.11.011","article-title":"Advancing the GI frontier for patients with CF","volume":"17","author":"Freedman","year":"2018","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1177\/2050640619841545","article-title":"A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders","volume":"7","author":"Hayee","year":"2019","journal-title":"United Eur. Gastroenterology J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/MPG.0000000000003357","article-title":"Abdominal Symptoms Assessed With the CFAbd-Score are Associated With Intestinal Inflammation in Patients With Cystic Fibrosis","volume":"74","author":"Jaudszus","year":"2022","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40271-019-00361-2","article-title":"Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score)","volume":"12","author":"Jaudszus","year":"2019","journal-title":"Patient"},{"key":"B15","doi-asserted-by":"publisher","first-page":"111124","DOI":"10.1016\/j.nut.2020.111124","article-title":"Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extension","volume":"85","author":"King","year":"2021","journal-title":"Nutrition"},{"key":"B16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.arbres.2017.09.012","article-title":"Effects of Ivacaftor in Three Pediatric Siblings With Cystic Fibrosis Carrying the Mutations G551D And F508del","volume":"54","author":"Mainz","year":"2018","journal-title":"Arch. Bronconeumol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"877118","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.10.001","article-title":"Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged \u226512 years - The RECOVER study","author":"Mainz","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jcf.2015.09.002","article-title":"Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies","volume":"15","author":"Martin","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"B20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jclinepi.2010.02.006","article-title":"The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes","volume":"63","author":"Mokkink","year":"2010","journal-title":"J. Clin. Epidemiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jcf.2016.02.002","article-title":"International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcome","volume":"15","author":"Munck","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"B22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jcf.2011.07.010","article-title":"Recurrent abdominal pain in children with cystic fibrosis: a pilot prospective longitudinal evaluation of characteristics and management","volume":"11","author":"Munck","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"B23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jcf.2020.06.004","article-title":"Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging","volume":"20","author":"Ng","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1007\/s10620-006-9185-2","article-title":"Nocturnal hydration--an effective modality to reduce recurrent abdominal pain and recurrent pancreatitis in patients with adult-onset cystic fibrosis","volume":"51","author":"Obideen","year":"2006","journal-title":"Dig. Dis. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrgastro.2015.226","article-title":"Cystic fibrosis from the gastroenterologist's perspective","volume":"13","author":"Ooi","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrgastro.2015.226","article-title":"Cystic fibrosis from the gastroenterologist's perspective","volume":"13","author":"Ooi","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(03)12567-6","article-title":"Cystic fibrosis","volume":"361","author":"Ratjen","year":"2003","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/apa.16143","article-title":"Impact of timing of PERT on gastrointestinal symptoms in Danish children and adolescents with CF","volume":"111","author":"Raun","year":"2022","journal-title":"Acta Paediatr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jcf.2021.08.021","article-title":"Diagnosing constipation in patients with cystic fibrosis applying ESPGHAN criteria","volume":"21","author":"Stefano","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0174463","DOI":"10.1371\/journal.pone.0174463","article-title":"Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings","volume":"12","author":"Tabori","year":"","journal-title":"PLoS One"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17465","DOI":"10.1038\/s41598-017-17302-4","article-title":"Relation of Ultrasound Findings and Abdominal Symptoms obtained with the CFAbd-Score in Cystic Fibrosis Patients","volume":"7","author":"Tabori","year":"","journal-title":"Sci. Rep."},{"key":"B1","volume-title":"Guidance document: patient-reported Outcome measures: use in medical product development to support labeling claims2009 10\/17\/2019","year":"2019"},{"key":"B34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clnesp.2018.06.008","article-title":"Probiotics in cystic fibrosis patients: A double blind crossover placebo controlled study: Pilot study from the ESPGHAN Working Group on Pancreas\/CF","volume":"27","author":"Van Biervliet","year":"2018","journal-title":"Clin. Nutr. ESPEN"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1167407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T22:13:34Z","timestamp":1699308814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1167407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":34,"alternative-id":["10.3389\/fphar.2023.1167407"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1167407","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.07.31.23293088","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"article-number":"1167407"}}